medQ Inc., provider of enterprise imaging workflow solutions, announced their collaboration with Advanced Medical Imaging of Lincoln, Neb., to customize the front end of AMI’s Q/ris 3000 electronic health record (EHR) to accommodate the need to automate and manage their Mammo Club operations.

October 26, 2017 — Ziehm Vision FD has been recognized with the Silver Stevie Award as "Best new product of the year" in the "Health & Pharmaceuticals" category at the 2017 Stevie Awards ceremony on Oct. 21 in Barcelona, Spain. The jury highlighted the improved clinical outcome and the cost-efficiency of Ziehm Vision FD that has set new standards in intraoperative imaging.

A research team led by Eva Dyer, a computational neuroscientist and electrical engineer, has successfully imaged brains at a map-like or “meso” scale using the most powerful X-ray beams in the country. The imaging scale gives an overview of the intercellular landscape of the brain at a level relevant to small neural networks, which are at the core of the brain’s computational abilities.

October 26, 2017 — Iradimed Corp. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its 3880 Magnetic Resonance Imaging (MRI)-compatible patient vital signs monitoring system.

The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF Kankerbestrijding) to test whether a novel molecular imaging technology can guide prostate cancer surgery. The project will evaluate the imaging technology’s ability to detect prostate cancer during surgery, with the aim of performing more accurate removal of cancerous tissue.

In a potential major breakthrough in breast cancer research, scientists at the Center for Translational Cancer Research (CTCR) at the Helen F. Graham Cancer Center & Research Institute of Christiana Care Health System have developed a new blood test to https://www.itnonline.com/channel/oncology-diagnosticsdiagnose breast cancer.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/CT (positron emission tomography/computed tomography) in restaging and treatment response assessment of malignant disease. As cancer patients move through therapy, FDG PET/CT has proven an effective tool for assessing treatment response and updating the stage of malignancy. This AUC aims to improve utilization and guide providers across specialties in its use.

Varian recently announced an 80-year-old male with head and neck cancer became the first patient in Europe to be treated on the Halcyon system at University Hospitals Leuven (UZ Leuven) in Belgium. Halcyon is an advanced cancer treatment system that is more comfortable for the patient while delivering ease-of-use for healthcare providers, accelerated installation timeframes, expedited commissioning, simplified training and automated treatment.

October 25, 2017 — ViewRay Inc. announced outcomes data presented during the recent 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego. This data highlighted compelling early results using the company's magnetic resonance imaging (MRI)-guided MRIdian radiation therapy system for the treatment of inoperable, locally advanced pancreatic cancer.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now